JIP
CRSP icon

Jaffetilchin Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Jaffetilchin Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,208
Closed -$205K – 413
2024
Q4 		$205K Buy
5,208
+1,889
+57% +$89.2K 0.01% 368
2024
Q3 		$156K Buy
+3,319
New +$168K 0.01% 393
2023
Q4 		– Sell
-4,949
Closed -$225K – 351
2023
Q3 		$225K Buy
4,949
+810
+20% +$41.8K 0.02% 307
2023
Q2 		$232K Buy
+4,139
New +$235K 0.02% 320
2022
Q3 		– Sell
-3,538
Closed -$215K – 322
2022
Q2 		$215K Buy
+3,538
New +$208K 0.03% 294

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jaffetilchin Investment Partners's CRSP Position: Q1 2025 in Review

Jaffetilchin Investment Partners sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 5,208 shares — an estimated $205K sold.

Jaffetilchin Investment Partners first reported a position in CRSP in Q2 2022 and held it in 5 quarters. The position peaked at $232K in Q2 2023. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Jaffetilchin Investment Partners reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 5,208 CRISPR Therapeutics shares in Q1 2025, an estimated $205K.
  • Jaffetilchin Investment Partners first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 5 quarters.
  • Jaffetilchin Investment Partners's CRISPR Therapeutics position peaked at $232K in Q2 2023.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q1 2025, filed 24 Apr 2025.